Table 1 Pretreatment characteristics of 201 hepatocellular carcinoma patients

Age, mean (SD)

61.7 (11.7)

61.9 (11.3)

61.0 (12.3)

0.694

Sex, n (%)

0.309

  Male

170 (84.6%)

99 (86.8%)

71 (81.6%)

  Female

31 (15.4%)

15 (13.2%)

16 (18.4%)

Viral hepatitis carrier, n (%)

  Viral hepatitis B

99 (49.3%)

57 (50.0%)

42 (48.2%)

0.809

  Viral hepatitis C

38 (18.9%)

22 (19.3%)

16 (18.3%)

0.871

Presence of main portal vein thrombosis, n (%)

76 (37.8%)

41 (35.9%)

35 (40.2%)

0.537

Other treatments, n (%)

  Surgery

25 (12.4%)

18 (15.8%)

7 (8.0%)

0.099

  TACE

127 (63.2%)

77 (67.5%)

50 (57.5%)

0.142

Tumor size (cm), mean (SD)

7.8 (4.1)

7.5 (3.9)

8.3 (4.3)

0.185

Baseline liver function test, mean (SD)

  AST (U/L)

68.6 (41.8)

62.8 (38.2)

76.1 (45.1)

0.029

  ALT (U/L)

44.7 (28.8)

43.2 (27.7)

46.7 (30.2)

0.392

  Total bilirubin (mg/dL)

1.4 (0.7)

1.1 (0.6)

1.3 (0.8)

0.043

Baseline ALBI score, mean (SD)

-2.28 (0.43)

-2.24 (0.37)

-2.19 (0.50)

0.377

Baseline ALBI, n (%)

< 0.001

  Grade 1

42 (20.9%)

12 (10.5%)

30 (34.5%)

  Grade 2

159 (79.1%)

102 (89.5%)

57 (65.5%)

Radiotherapy techniques, n (%)

  3D-CRT

66 (32.8%)

35 (30.7%)

31 (35.6%)

0.461

  IMRT, VMAT

93 (46.3%)

55 (48.2%)

38 (43.7%)

0.520

  SBRT

42 (20.9%)

24 (21.1%)

18 (20.7%)

0.950

Dose-volume data, median (IQR)

  Total dose (Gy)

33 (30–45)

40 (30–45)

30 (30–45)

0.097

  Number of fractions

10 (10–10)

10 (10–14)

10 (8–10)

0.120

Gross tumor volume (cm³)

177.8 (742.8)

155.0 (540.8)

264.4 (855.3)

0.100

Dose-volume data, mean (SD)

  Normal liver volume (cm³)

1231.3 (455.6)

1222.0 (403.6)

1243.4 (518.1)

0.742

  Normal liver gEUD at a = 1.0 or mean liver dose (Gy)

17.6 (8.0)

16.8 (7.2)

18.7 (8.8)

0.088